ArticleFrontiers in endocrinology2026
Plasma R-spondin 2 levels are associated with the progression of diabetic kidney disease.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Circulating factor R-spondin 2 (RSPO2) has been found to play a role in lipid metabolism and insulin resistance. However, its relationship with kidney injury and diabetic kidney disease (DKD) remains unclear. We aim to determine the expression levels of RSPO2 in patients with type 2 diabetes mellitus (T2DM) stratified by kidney disease risk, and analyze its correlations with the parameters of renal injury parameters, glucose and lipid profiles, and further investigate the association between plasma RSPO2 concentration and the prognosis risk of DKD. Methods: A total of 121 participants with T2DM were enrolled and categorized into four kidney disease risk groups (Low, Moderately Increased, High, and Very High Risk) based on estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR). Relevant anthropometric and biochemical parameters were analyzed, and plasma RSPO2 concentrations were measured. Spearman's correlation analysis and Multiple logistic regression analysis was conducted. Results: Plasma RSPO2 concentrations were significantly elevated in the High and Very High Risk groups compared to the Low and Moderately Increased Risk groups. Conclusions: Elevated plasma RSPO2 concentration is independently associated with higher kidney disease risk in patients with T2DM and may serve as a potential biomarker for DKD progression. Further studies are needed to elucidate the role of RSPO2 in DKD and its underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.